DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Zalfermin

Generic Name: Zalfermin

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

Phase 2

Active, not recruiting

Posted: 2024/05/10

Sponsor:Novo Nordisk A/S

A Research Study Looking at How the Compound NNC0194-0499 Works With Birth Control Pills in Women Not Able to Bear Children.

Phase 1

Completed

Posted: 2024/01/03

Sponsor:Novo Nordisk A/S

A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function

Phase 1

Completed

Posted: 2023/06/26

Sponsor:Novo Nordisk A/S

A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations

Phase 1

Completed

Posted: 2023/03/13

Sponsor:Novo Nordisk A/S

A Research Study Looking at How a Single Dose of the Medicine NNC0194-0499 Behaves in Chinese Men

Phase 1

Completed

Posted: 2023/02/24

Sponsor:Novo Nordisk A/S

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Novo Nordisk Explores GLP-1 Drugs' Potential in Addiction Treatment

3 months ago

Novo Nordisk is expanding its GLP-1 research beyond diabetes and obesity, investigating the potential therapeutic applications for addiction treatment.

NASH Treatment Market to Reach Significant Growth by 2032, Driven by Emerging Therapies

6 months ago

The non-alcoholic steatohepatitis (NASH) market is poised for substantial growth, projected to expand significantly by 2032 across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy